Product information and disease descriptionProduct description
Phase of product development
23 evidence topics · 19 sources
Regulatory status: Under review; NDA submitted in the third quarter of 2026
Launch
No evidence found.
Commercial preparation for a potential U.S. launch
Investigational status
FDA agreement to review the NDA under the Real-Time Oncology Review program
FDA acceptance, priority review, and action date
No evidence found.
Accelerated approval on progression-free survival with overall survival for full approval
FDA orphan drug designation for uveal melanoma, April 2022
| Field | Quoted record |
|---|---|
| Generic name | “darovasertib” |
| Date designated | “04/27/2022” |
| Orphan designation | “Treatment of Uveal Melanoma” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “IDEAYA Biosciences Inc.” |
Fast Track designation for darovasertib with crizotinib in metastatic uveal melanoma, November 2022
Breakthrough Therapy designation for neoadjuvant monotherapy in primary uveal melanoma, March 2025
FDA designations as summarized by the company, October 2026
European Union orphan designation for uveal melanoma, August 2025
Origin at Novartis and the 2018 license to IDEAYA
“Herein, we describe the discovery of darovasertib (NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LXS196 is being investigated in the clinic as a monotherapy and in combination with other agents for the treatment of uveal melanoma (UM), including primary UM and metastatic uveal melanoma (MUM).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote